158654-83-2

Basic information

• Product Name: (S)-3-(Toluene-4-sulfonyloxy)-pyrrolidine-1-carboxylic acid benzyl ester
• Synonyms: (S)-3-(Toluene-4-sulfonyloxy)-pyrrolidine-1-carboxylic acid benzyl ester;(S)-Benzyl 3-(tosyloxy)pyrrolidine-1-carboxylate;benzyl (3S)-3-[(4-methylbenzenesulfonyl)oxy]pyrrolidine-1-carboxylate;1-Pyrrolidinecarboxylic acid, 3-[[(4-methylphenyl)sulfonyl]oxy]-, phenylmethyl ester, (3S)-
• CAS NO: 158654-83-2
• Molecular Formula: C₁₉H₂₁NO₅S
• Molecular Weight: 375.43874
• Mol File: 158654-83-2.mol

Chemical Properties

• Boiling Point: 537.9±50.0 °C(Predicted)
• Appearance: /
• Density: 1.33±0.1 g/cm3(Predicted)
• PKA: -3.63±0.40(Predicted)
• CAS DataBase Reference: (S)-3-(Toluene-4-sulfonyloxy)-pyrrolidine-1-carboxylic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-(Toluene-4-sulfonyloxy)-pyrrolidine-1-carboxylic acid benzyl ester(158654-83-2)
• EPA Substance Registry System: (S)-3-(Toluene-4-sulfonyloxy)-pyrrolidine-1-carboxylic acid benzyl ester(158654-83-2)

Safety Data

• Hazardous Substances Data: 158654-83-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(S)-3-(Toluene-4-sulfonyloxy)-pyrrolidine-1-carboxylic acid benzyl ester is used as a synthetic intermediate for the preparation of various complex organic molecules. Its unique functional groups and chiral center allow for selective reactions and the formation of diverse chemical products.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (S)-3-(Toluene-4-sulfonyloxy)-pyrrolidine-1-carboxylic acid benzyl ester is used as a potential lead compound for the development of new pharmaceuticals. Its specific structural features may offer novel binding interactions with biological targets, leading to the discovery of new therapeutic agents.
Used in Pharmaceutical Industry:
(S)-3-(Toluene-4-sulfonyloxy)-pyrrolidine-1-carboxylic acid benzyl ester is used as a key component in the synthesis of pharmaceuticals, particularly for drugs targeting specific receptors or enzymes. Its chirality and functional groups may contribute to the optimization of drug candidates, enhancing their efficacy and selectivity.
Additional research and testing are required to fully explore the potential uses and properties of (S)-3-(Toluene-4-sulfonyloxy)-pyrrolidine-1-carboxylic acid benzyl ester, as its applications in different industries may vary based on its reactivity and interactions with other molecules.

Upstream product

• 13438-45-4 zinc(II) tosylate 
• 100858-33-1 (3R)-3-hydroxy-pyrrolidine-1-carboxylic acid benzyl ester 
• 501-53-1 benzyl chloroformate 
• 100858-32-0 (S)-3-hydroxy-1-pyrrolidinecarboxylic acid phenylmethyl ester 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 192214-06-5 (R)-1-((benzyloxy)-carbonyl)pyrrolidine-3-carboxylic acid 
• 329012-80-8 3-cyanopyrrolidine-1-carboxylic acid benzyl ester 

Relevant articles and documents

COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), Formula (II), or Formula (III), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Stability against enzymatic hydrolysis of endomorphin-1 analogues containing β-proline

The enantiomer of endomorphin-1 (Tyr-Pro-Trp-PheNH2) and the analogues containing (S)-or (R)-β-proline have been synthesized, and their affinities towards μ-opioid receptors have been measured. As expected, the incubations of the different peptides with some commercially available enzymes showed that the presence of D-residues gave strong resistance towards digestion. The presence of β-proline alone is sufficient to confer good resistance against the hydrolysis of the biologically strategic Pro-Trp bond.

Synthesis and binding activity of endomorphin-1 analogues β-amino acids

Endomorphin-1 (Tyr-Pro-Trp-PheNH2) has been proposed as the most potent endogenous ligand of the μ-opioid receptors. In this paper, we describe the synthesis of some endomorphin-1 based tetrapeptides in which a residue of the sequence Tyr-Pro-Trp-PheNH2 is replaced by the corresponding β-isomer. These novel peptides showed different affinities for the opioid receptors labeled with [3H]-DAMGO in rat brain membranes, depending on the β-amino acid. In particular, the tetrapeptide containing β-Pro (Tyr-β-(R)-Pro-Trp-PheNH2) displayed a higher affinity than endogenous endomorphin-1, as revealed by their K(i) values (0.33 and 11.1 nM, respectively). (C) 2000 Elsevier Science Ltd.

Constrained β-alanine based GpIIb/IIIa antagonists

The concepts of centrally constrained and peptide based fibrinogen receptor antagonists have been successfully combined into a single series of analogs which have been demonstrated to be potent inhibitors of platelet aggregation.